Otsuka's Kidney Disease Drug Achieves Over 50% Reduction in Urinary Protein Levels
Otsuka's experimental drug sibeprenlimab showed promising results in reducing toxic protein levels in patients with IgA nephropathy, outperforming Vera Therapeutics in a Phase 3 study, with fewer serious side effects.
